Company Overview and News
Gold explorer Geopacific Resources has raised $10 million in exploration funding for its Woodlark gold project in Milne Bay, Papua New Guinea.
New Century Resources has raised $40 million to complete the restart of its zinc mine in Queensland, while Vimy Resources and Geopacific Resources have tapped investors for $6 million and $10 million respectively.
Geopacific Resources Ltd (ASX:GPR) is moving towards a development decision at the Woodlark Gold Project in Papua New Guinea after receiving positive prefeasibility study (PFS) results.
Geopacific Resources Ltd (ASX:GPR) has identified new gold intersections at its Woodlark Gold Project located in Papua New Guinea.
Geopacific Resources has acquired a majority stake in Kula Gold after the takeover target’s largest shareholder accepted Geopacific’s recently increased offer.
Geopacific Resources (ASX:GPR) has received new assay results intersecting up to 21 metres at 3.27 g/t gold at the Woodlark Gold Project in Papua New Guinea.
Kula Gold (ASX:KGD) has received further ongoing high grade gold assays from its drilling program at the flagship Woodlark Island Project in Papua New Guinea.
Perth-based explorer Kula Gold says it could save $US25 million, or 27 per cent, in the costs of building its Woodlark Island gold project in Papua New Guinea if done so in the current economic environment.
Kula requested the halt pending drill results on the Woodlark Island Gold project as announced by JV partner, Geopacific Resources (ASX:GPR), on 25 January 2017 and to engage a competent person to sign off on the competent person statement.
Resource Capital Gold Corp., (TSX VENTURE: RCG) ("RCG" or the "Company") is pleased to announce that Dr. Ian J. Pringle and Mr. Gary L. Lewis have joined its board as non-executive director and non-executive chairman respectively. Mr. Ian Mitchell has stepped down from the board for personal reasons. Dr. Pringle and Mr. Lewis join Dr. Michael G. Nelson and Mr. George S. Young on the board and bring additional technical strength and business acumen to the Company as it commences mining and milling operations in Nova Scotia, and continues to build its asset base in North America.
A record high Australian dollar price in June has provided a tailwind for the state’s gold sector, and 2017 is looking to be a similarly positive year.
Local explorer Geopacific Resources has kicked off a $15 million capital raising to fund the earn-in, and development, of the Woodlark gold project in Papua New Guinea.
Geopacific Resources Ltd (ASX:GPR) is raising funds for gold exploration in Cambodia. The ASX has granted the company a trading halt to prepare, with its shares placed in pre-open. The halt will remain in place until the opening of trade on Thursday 18th August 2016, or earlier if an announcement is made to the market.
Perth-based explorer Geopacific Resources has entered into an agreement to farm-in to Kula Gold’s Woodlark Island gold project in Papua New Guinea, in a deal worth up to $18.6 million.
12h - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
12h - Asif
Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...
22h - Asif
Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...